NMK 150

Drug Profile

NMK 150

Alternative Names: NMK-150

Latest Information Update: 11 Aug 2011

Price : $50

At a glance

  • Originator Axcan Pharma; Norax
  • Developer Aptalis
  • Class Peptide hydrolases
  • Mechanism of Action Pancrelipase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Visceral pain

Most Recent Events

  • 29 Nov 2007 Phase-I development is ongoing
  • 08 May 2006 Phase-I clinical trials in Visceral pain in Canada (PO)
  • 27 Mar 2003 Preclinical trials in Visceral pain in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top